XW033Q5Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5
- Billable / Specific Code
XW033Q5 is a billable ICD-10-PCS procedure code for Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products.
Code Identity
PCS Table Breakdown
Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.
| Position | Designation | Value | Meaning |
|---|---|---|---|
| 1 | Section | X | New Technology |
| 2 | Body System | W | Anatomical Regions |
| 3 | Operation | 0 | Introduction |
| 4 | BodyPart | 3 | Peripheral Vein |
| 5 | Approach | 3 | Percutaneous |
| 6 | Device/Substance/Technology | Q | Tagraxofusp-erzs Antineoplastic |
| 7 | Qualifier | 5 | New Technology Group 5 |
Code History
- 3E03305 — Introduce Oth Antineoplastic in Periph Vein, Perc
Similar Procedure Codes
Questions About XW033Q5
Is XW033Q5 a billable code?
Yes. XW033Q5 is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5 on inpatient claims from October 1, 2025 through September 30, 2026.
What do the characters in XW033Q5 mean?
XW033Q5 breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 3 is the BodyPart (Peripheral Vein); the 5th character 3 is the Approach (Percutaneous); the 6th character Q is the Device/Substance/Technology (Tagraxofusp-erzs Antineoplastic); the 7th character 5 is the Qualifier (New Technology Group 5).
